Evidence map›Paper›PMID 42866949›Full record

ArticleNucleic acids research2026

Double-base deletions and signatures associated with platinum adducts in metastatic cancer.

Marcel Smid, Lotte van Leeuwen, Saskia M Wilting, John W M Martens

Abstract read
In one paragraph

Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Marcel SmidDepartment of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD, Rotterdam, The Netherlands.ORCID 0000-0003-0605-1901
Lotte van LeeuwenDepartment of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD, Rotterdam, The Netherlands.ORCID 0009-0008-1323-7054
Saskia M WiltingDepartment of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD, Rotterdam, The Netherlands.
John W M MartensDepartment of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD, Rotterdam, The Netherlands.ORCID 0000-0002-3428-3366

Funding

Dutch Cancer Society KWF14976
6 · The paper itself

Abstract

Platinum compounds preferably create intrastrand G-G adducts to halt replication in cancer cells. When successfully bypassed, resulting somatic variants end up in the genome. Unexpectedly, current double-base substitution signatures associated with platinum lack a GG component, and we hypothesized that deletion was missing from the possible solutions to circumvent a double-base lesion. We investigated a large pan-cancer metastatic cohort and generated platinum specific de novo double-base substitution and deletion (DBSD) signatures. One of the oxaliplatin associated DBSD signatures had GG deletion as dominant characteristic and also included new and known substitutions associated with platinum. Unforeseen among the additional results, DBSD signatures with deletion of TT as singular characteristic were strongly associated with microsatellite instability in multiple cohorts and provisionally in liquid biopsies. This study showed that DBSD signatures increase our understanding and cataloging of the effects caused by platinum and, in general, may aid in the discovery of new biological insights.

Indexed as

Antineoplastic AgentsDNA AdductsNeoplasmsOrganoplatinum CompoundsSequence DeletionCisplatinHumansMicrosatellite InstabilityNeoplasm MetastasisOxaliplatinAntineoplastic AgentsCisplatinDNA AdductsOrganoplatinum CompoundsOxaliplatin

Identifiers

PMID42866949
PMCPMC13659239

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.